Lenalidomid Piramal (Lenalidomide)

Lenalidomide binds to cereblon, a component of the CRL4‑E3 ubiquitin ligase complex, altering the complex’s substrate specificity. This triggers degradation of transcription factors Ikaros and Aiolos, leading to reduced cytokine production, inhibition of angiogenesis, enhanced T‑ and NK‑cell activity, and direct apoptosis of malignant plasma cells.

The prescribed dose is individualized by the treating physician based on the specific indication, disease stage, patient weight, renal function, and any concomitant therapies. Dosage adjustments may be required for patients with impaired kidney function or those receiving interacting medications.

Lenalidomid Piramal is classified as Pregnancy Category X, meaning it is contraindicated in pregnancy because of a high risk of fetal harm. Women of child‑bearing potential must use effective contraception. The drug is also not recommended while breastfeeding, as it may be excreted in milk.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

Both lenalidomide and thalidomide belong to the immunomodulatory drug (IMiD) class, but lenalidomide has a more potent anti‑angiogenic and immune‑activating profile, a shorter half‑life, and a different side‑effect spectrum. Lenalidomide generally shows higher efficacy in multiple myeloma and a lower incidence of peripheral neuropathy compared with thalidomide.

Store Lenalidomid Piramal at temperatures below 25 °C in its original container, protecting it from moisture, light and excessive heat. Keep the product out of reach of children and avoid crushing or splitting tablets unless specifically instructed by a pharmacist.

Lenalidomid Piramal is taken orally, usually as a whole tablet swallowed with water. It is typically administered once daily on a schedule defined by the prescriber, often in cycles that include treatment days followed by rest periods to allow blood‑cell recovery.

Serious risks include venous thromboembolism, severe neutropenia that can lead to infection, secondary primary malignancies, and rare but life‑threatening skin reactions such as Stevens‑Johnson syndrome. Patients should be monitored closely for signs of clotting, infection, or unusual skin changes.

Lenalidomid Piramal should not be used by pregnant women, individuals with known hypersensitivity to lenalidomide or its excipients, and patients with severe renal impairment unless dose adjustments are made. It is also contraindicated in patients with a history of thromboembolic events unless appropriate prophylaxis is in place.